Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia‐Manero, Lewis R. Silverman, Pierre Fenaux et al.|The Lancet Oncology|2016Cited by 172
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid LeukemiaPinkal Desai, Farhad Ravandi, Olga Frankfurt et al.|Journal of Clinical Oncology|2021Cited by 21
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Habte Yimer et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction RegimenRobert M. Rifkin, Stephen J. Noga, Ralph V. Boccia et al.|Blood|2017Cited by 5